GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Current Deferred Revenue

Kyverna Therapeutics (Kyverna Therapeutics) Current Deferred Revenue : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Kyverna Therapeutics's current deferred revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.

Kyverna Therapeutics Current Deferred Revenue Historical Data

The historical data trend for Kyverna Therapeutics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Current Deferred Revenue Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Current Deferred Revenue
6.00 - -

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Current Deferred Revenue Get a 7-Day Free Trial - - - - -

Kyverna Therapeutics Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines